Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Sunshine Biopharma (SBFM) over the last 11 years, with Sep 2025 value amounting to $3.5 million.

  • Sunshine Biopharma's Non-Current Assets fell 13.62% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 13.62%. This contributed to the annual value of $4.6 million for FY2024, which is 86.98% up from last year.
  • Sunshine Biopharma's Non-Current Assets amounted to $3.5 million in Q3 2025, which was down 14.44% from $4.1 million recorded in Q2 2025.
  • Sunshine Biopharma's Non-Current Assets' 5-year high stood at $4.7 million during Q1 2025, with a 5-year trough of $1,642 in Q2 2022.
  • For the 3-year period, Sunshine Biopharma's Non-Current Assets averaged around $3.3 million, with its median value being $3.5 million (2025).
  • As far as peak fluctuations go, Sunshine Biopharma's Non-Current Assets crashed by 87.82% in 2022, and later surged by 140,662.06% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Non-Current Assets (Quarterly) stood at $7,061 in 2021, then skyrocketed by 27,254.68% to $1.9 million in 2022, then climbed by 27.20% to $2.5 million in 2023, then surged by 86.98% to $4.6 million in 2024, then decreased by 13.62% to $3.5 million in 2025.
  • Its Non-Current Assets stands at $3.5 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.7 million for Q1 2025.